Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HACER: Infliximab for Hip Arthritis in AS
NCT01148901Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jun 2010
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of infliximab in ankylosing spondylitis (AS), sponsored by Merck & Co. Primary endpoint: Western Ontario and McMaster University Osteoarthritis Index at Week 15. Planned start Jun 2010; status: withdrawn.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01148901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148901.